Avalo Therapeutics (AVTX) Cash from Financing Activities (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Cash from Financing Activities data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (down 76.22% YoY) and the FY2025 annual result came in at $14.6 million, down 91.7% from the prior year.
• Cash from Financing Activities advanced to $1.4 million in Q1 2026, from $687000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q1 2024 to a low of -$14.8 million in Q2 2022.
• A 5-year average of $15.6 million and a median of $687000.0 in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 6770800.0% in 2024, down 178.93% in 2024.
• Tracing AVTX's Cash from Financing Activities over 5 years: stood at $82000.0 in 2022, then sank by 98.78% to $1000.0 in 2023, then jumped by 6770800.0% to $67.7 million in 2024, then slumped by 98.99% to $687000.0 in 2025, then jumped by 103.64% to $1.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.4 million (Q1 2026), $687000.0 (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.